| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
11,253 |
9,690 |
$480K |
| 84443 |
Thyroid stimulating hormone (TSH) |
18,346 |
15,881 |
$314K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
11,217 |
10,108 |
$272K |
| 80061 |
Lipid panel |
18,250 |
15,914 |
$253K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,594 |
4,336 |
$230K |
| 80053 |
Comprehensive metabolic panel |
18,907 |
16,294 |
$207K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
28,029 |
23,703 |
$187K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
4,950 |
4,332 |
$128K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
9,798 |
8,533 |
$96K |
| 87276 |
|
6,840 |
5,770 |
$75K |
| 86738 |
|
6,147 |
5,262 |
$71K |
| 81000 |
|
21,421 |
18,434 |
$71K |
| 87275 |
|
6,836 |
5,769 |
$70K |
| 84439 |
|
6,232 |
5,299 |
$50K |
| 82274 |
|
3,242 |
2,848 |
$43K |
| 86328 |
|
1,718 |
1,616 |
$34K |
| 86701 |
|
4,210 |
3,643 |
$34K |
| 87088 |
|
3,265 |
2,750 |
$28K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
816 |
638 |
$27K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
517 |
469 |
$27K |
| 82043 |
|
5,347 |
4,667 |
$26K |
| 82607 |
|
1,814 |
1,518 |
$25K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,067 |
2,752 |
$25K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
719 |
601 |
$24K |
| 84153 |
|
1,456 |
1,362 |
$21K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,004 |
2,510 |
$20K |
| 80074 |
|
351 |
285 |
$16K |
| 84436 |
|
2,510 |
2,245 |
$15K |
| 36415 |
Collection of venous blood by venipuncture |
3,598 |
3,308 |
$13K |
| 86592 |
|
3,385 |
2,926 |
$13K |
| 84479 |
|
2,296 |
2,059 |
$12K |
| 85027 |
|
1,904 |
1,585 |
$11K |
| 86803 |
|
677 |
552 |
$9K |
| 87490 |
|
403 |
365 |
$7K |
| 82570 |
|
1,297 |
962 |
$6K |
| 87590 |
|
343 |
308 |
$6K |
| 85651 |
|
1,595 |
1,461 |
$5K |
| 85730 |
|
832 |
705 |
$4K |
| 82951 |
|
355 |
265 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
52 |
37 |
$4K |
| 86769 |
|
85 |
83 |
$3K |
| 87899 |
|
252 |
210 |
$3K |
| 84703 |
|
537 |
487 |
$3K |
| 85610 |
|
806 |
688 |
$3K |
| 83001 |
|
138 |
111 |
$2K |
| 86038 |
|
169 |
155 |
$2K |
| 84550 |
|
329 |
258 |
$1K |
| 82950 |
|
308 |
270 |
$1K |
| 83002 |
|
71 |
57 |
$1K |
| 83540 |
|
200 |
177 |
$1K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
1,017 |
864 |
$1K |
| 83655 |
|
96 |
88 |
$1K |
| 82947 |
|
316 |
267 |
$1K |
| 86696 |
|
45 |
26 |
$861.35 |
| 84146 |
|
46 |
43 |
$829.34 |
| 80050 |
General health panel |
121 |
87 |
$820.31 |
| 87177 |
|
132 |
126 |
$788.97 |
| 86140 |
|
137 |
117 |
$634.61 |
| 84702 |
|
46 |
29 |
$604.07 |
| 86695 |
|
30 |
13 |
$396.28 |
| 82746 |
|
30 |
27 |
$387.34 |
| 82728 |
|
29 |
25 |
$371.47 |
| 87340 |
|
24 |
12 |
$246.96 |
| 84160 |
|
34 |
14 |
$190.74 |
| 86900 |
|
39 |
39 |
$115.53 |
| 86901 |
|
39 |
39 |
$115.53 |
| 81001 |
|
30 |
30 |
$114.30 |
| 84460 |
|
52 |
49 |
$83.57 |
| 82565 |
|
15 |
12 |
$71.68 |
| 86886 |
|
13 |
13 |
$62.11 |
| 86430 |
|
21 |
15 |
$51.03 |
| 84450 |
|
24 |
24 |
$44.04 |
| 87084 |
|
17 |
17 |
$29.24 |